AEterna Zentaris (AEZS) : 3 brokerage houses believe that AEterna Zentaris (AEZS) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 4 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.25.
AEterna Zentaris (AEZS) : The highest short term price target forecast on AEterna Zentaris (AEZS) is $12 and the lowest target price is $10. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $11 with a standard deviation of $0.82.
Shares of Aeterna Zentaris Inc. rose by 0.55% in the last five trading days and 10.21% for the last 4 weeks. Aeterna Zentaris Inc. is up 6.07% in the last 3-month period. Year-to-Date the stock performance stands at -18.08%. AEterna Zentaris (NASDAQ:AEZS): The stock was completely flat for the day, closing at $3.67 on Tuesday. The flat closing masks the intraday volatility in the stock. After opening at $3.67, the stock touched an intraday high of $3.72 and a low of $3.61. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $3.67. The total trading volume on Tuesday was 64,525.
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and womens health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent, doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.